Landmark Outcomes Study Shows That Repatha® (Evolocumab) Decreases LDL-C To Unprecedented Low Levels And Reduces Risk Of Cardiovascular Events With No New Safety Issues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall St set for lower open as AI jitters rekindle, oil gains
- Brent hits five-month high on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- JPMorgan says AI stock selling may be nearing its limit as positioning resets
| Amgen Inc (NASDAQ: AMGN) | Delayed: 442.68 +4.34 (0.99%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $438.34 | 52 Week High | $176.85 | |||
| Open | $441.55 | 52 Week Low | $133.64 | |||
| Day High | $443.72 | P/E | 66.67 | |||
| Day Low | $437.19 | EPS | $6.64 | |||
| Volume | 241,020 | |||||
